Author:
Murakawa Yasuko,Ootsuka Kazunori,Kusaka Jun,Miura Kou
Abstract
Abstract
Background
Patients presenting with inoperable colon cancer at first onset (ICF) or at time of relapse (ICR) are considered in unrecoverable. The therapeutic goal for unrecoverable cancer is to prolong overall survival (OS) and maintain a high quality of life (QOL). As data on objective indicators of QOL in cancer patients, such as length of hospitalisation (LOH), outpatient consultation times (OCT), and hospital-free survival (HFS), is limited, this study compared ICF and ICR with respect to OS and QOL over the entire clinical course.
Methods
We retrospectively evaluated 90 inoperable colon cancer patients with chemotherapy and compared ICF and ICR in terms of OS, LOH, OCT, and HFS.
Results
Patients with ICF had a worse OS than those with ICR. In patients with ICF and ICR, OS and LOH were not correlated but OS and OCT and OS and HFS were strongly correlated. In patients with ICF and ICR, OCT and HFS accounted for approximately 8% and 90% of their OS, respectively.
Conclusions
The LOH, OCT, and HFS are important factors for evaluating objective QOL of patients with inoperable colon cancer and should be considered when making treatment decisions.
Publisher
Springer Science and Business Media LLC
Subject
Cancer Research,Genetics,Oncology
Reference32 articles.
1. Wang J, Li S, Liu Y, Zhang C, Li H, Lai L. Metastatic patterns and survival outcomes in patients with stage IV colon cancer: A population-based analysis. Cancer Med. 2020;9(1):361–73. https://doi.org/10.1002/cam4.2673.
2. American Cancer Society. Cancer Statistics Center. 2022 Estimates, Estimated deaths, 2022. Available from: https://cancerstatisticscenter.cancer.org/#!/. Accessed 10 May 2022.
3. National Cancer Center, Projected Cancer Statistics. Available from: https://ganjoho.jp/reg_stat/statistics/stat/short_pred_en.html. Accessed 10 May 2022.
4. Japanese Society for Cancer of the Colon and Rectum Rectum Guidelines 2022 for the Treatment of Colorectal Cancer. p97
5. de Gramont A, Hubbard J, Shi Q, O’Connell MJ, Buyse M, Benedetti J, et al. Association between disease-free survival and overall survival when survival is prolonged after recurrence in patients receiving cytotoxic adjuvant therapy for colon cancer: simulations based on the 20,800 patient ACCENT data set. J Clin Oncol. 2010;28(3):460–5. https://doi.org/10.1200/jco.2009.23.1407.